secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0000950170-23-005503
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q4 net loss $137.4M; FDA rejects omecamtiv mecarbil NDA
--------------------------------------------------------------------

- Net loss Q4 2022 $137.4M ($1.45/share) vs $30.6M ($0.36/share) in Q4 2021; full year loss $389.0M ($4.33/share).
- FDA issued Complete Response Letter for omecamtiv mecarbil NDA, citing insufficient evidence from GALACTIC-HF.
- Cash, cash equivalents and investments $829.3M at Dec 31, 2022; 2023 guidance: revenue up to $5M, operating expenses $420-450M.
- SEQUOIA-HCM (aficamten) enrollment complete in Q2 2023 with results expected Q4 2023; second interim analysis of COURAGE-ALS in Q2 2023.
- R&D expenses $75.0M in Q4 2022, up from $43.5M in Q4 2021; G&A $54.0M vs $33.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/0000950170-23-005503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/cytk-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer